Jerome Zeldis

Functions as a College/University

Functions as a College/University

Functions as a College/University

Operates as volunteer organization to prepare young people to make ethical choices

Provides research, advocacy and support services for various kinds of arthritis and related diseases

Develops commercial prophylactic vaccines and immunotherapy products

Functions as a College/University

Functions as a College/University

Operates as a clinical and commercial stage biopharmaceutical company that develops treatments for cancer, infectious disease and pain

Develops treatments for cancer

Manufactures hydrogel compounds

Manufactures nutritional supplements and vaccines

Operates as a biomedical company

Operates as a non-profit organization that improves maternal and child health by supporting women, communities and community health system

Develops cancer diagnostics technologies

Develops non-psychoactive cannabinoid medicines

Developing a platform of nitric oxide generators and delivery systems

Manufactures medicines for infectious diseases

Operates as a clinical-stage medical device and biopharmaceutical company

Israel Biotech invests in companies located in Israel. The firm targets companies operating in the fields of biotechnology and pharmaceutical sectors. It provides financing for early stage capital requirements.

Operates as a clinical-stage biotechnology company that develops and commercializes therapies for patients

Operates as a biotechnology company which produces allogeneic cells and tissues from postpartum placenta

Engages in drug discovery and development

Manufactures pharmaceutical products to fight SARS-CoV-2 virus that causes COVID-19

Greater New Jersey Title operates in the real estate industry and employs between 20 and 49 people, with revenue ranging from 1 to 5 million dollars. The private company is based in Iselin, NJ.

The private company is based in Paso Robles. The Castleman Disease Collaborative Network (CDCN) is a patient-founded nonprofit organization established in 2012 that focuses on accelerating research, improving treatment, and enhancing patient care for Castleman disease, a rare and complex group of inflammatory disorders. CDCN connects physicians, researchers, patients, and loved ones worldwide through online platforms, registries, forums, and summits to foster collaboration and scientific progress. The organization uses a community-driven approach to prioritize research questions, recruit scientists, and fund targeted studies, with a comprehensive research pipeline that includes patient enrollment, biospecimen collection, data analysis, and dissemination of findings. CDCN emphasizes drug repurposing and identification of new therapeutic targets, with clinical trials underway for treatments beyond the only FDA-approved drug for idiopathic multicentric Castleman disease. Key initiatives include the ACCELERATE natural history registry, the Castleman Disease Expert Panel, the IMCD Treatment Target Dashboard, and the Roadmap Project for drug repurposing. CDCN provides resources for patients, physicians, and researchers, such as toolkits, referral lists, support networks, educational materials, and regular updates.